Durvalumab
Durvalumab is a medication used in cancer treatment, specifically an immune checkpoint inhibitor. It works by helping the immune system recognize and attack cancer cells more effectively. By blocking a protein called PD-L1, durvalumab enhances the body's ability to fight tumors, particularly in cancers such as non-small cell lung cancer and bladder cancer. It is typically administered as an intravenous infusion and is part of a broader approach to immunotherapy, which aims to strengthen the immune response against cancer. Monitoring for side effects is important, as with any cancer treatment.
Additional Insights
-
Durvalumab is a type of medication known as an immune checkpoint inhibitor. It works by blocking a protein called PD-L1 found on some cancer cells, which helps tumors evade the immune system. By inhibiting this protein, Durvalumab aims to enhance the body's immune response against cancer, allowing it to recognize and attack tumor cells more effectively. It is primarily used to treat several types of cancer, including non-small cell lung cancer and bladder cancer. Patients receive it through an intravenous infusion under medical supervision, often as part of a more comprehensive treatment plan.